Floatz logo

Autologous Dendritic Cell-Adenovirus P53 Vaccine

Breast Cancer

University of NebraskavaccinePhase 1/2Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
34/ 100
Competitive Position
59/ 100

Competitive context

891 Active assets in the Breast Cancer cohort.

Asset / SponsorPhaseRating
Darolutamide
Vandana Abramson
Phase 2BBB
Palbociclib
Hoffmann-La Roche
Phase 4BB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
Ribociclib
National Cancer Institute (NCI)
Phase 4BB
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BB

View all 50 →

Same molecule, other indications

Autologous Dendritic Cell-Adenovirus P53 Vaccine is also rated in:

cutaneous melanomaDormant
CCC
Indicative ·
50 / 100
View asset →
cancer of unknown primary siteDormant
CCC
Indicative ·
50 / 100
View asset →
kidney cancerDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →